FDA Finds Contamination in Chinese Factories Producing Weight-Loss Drug Ingredients
According to a recent report, inspectors at the Food and Drug Administration (FDA) discovered significant contamination issues at two factories in China that manufacture components for GLP-1 weight-loss medications. The findings included mold and infestation by insects.
These factories, operated by compounding pharmacies, produce semaglutide and tirzepatide, which are the active ingredients found in popular weight-loss drugs from Novo Nordisk and Eli Lilly. Unfortunately, these versions of the drugs are unauthorized for sale by regulatory authorities, as stated by sources.
At the Chengdu Shengnuo Biopharm Co. facility, inspectors observed bugs in the ceiling and moldy floors. When inspectors arrived, it seemed that employees were purposefully disposing of product samples in sinks, according to the report.
Additionally, employees appeared to be hurriedly transferring documents out of a lab into a room nearby, stuffing them into lockers, as noted in records gathered under a Freedom of Information Act request. Inspectors mentioned they couldn’t recover all the documents.
The second factory, owned by Nanjing Chengong Pharmaceutical Co., reportedly had staff procuring active ingredients from other manufacturers and applying their company’s seal without properly reviewing any testing or safety documentation. That’s concerning, to say the least.
As a result of these findings, both companies were placed on the FDA’s import alert list, which means their products could be seized at the border. Notably, the actual drugs were not tested during this inspection process.
Chengdu Shengnuo Biopharm Co. claimed in a government filing that they have been taking diligent measures to address and rectify these problems.
Attempts to reach out to both labs and the FDA for comments went unanswered.
Michael Rogers, a former FDA investigator, expressed in an interview that these issues “suggest a serious accident waiting to happen.”
This situation is part of a larger problem involving compounded drugs, which are part of a billion-dollar industry dealing with unregulated peptides. The safety of these unregulated peptides remains largely unknown. Currently, the FDA is debating whether to allow overseas compounding pharmacies to produce various types of peptides, with some operating on the assumption that U.S. law permits the sale of imitations.
It’s worth mentioning that nearly fifteen years ago, contaminated drugs from the New England Compounding Pharmacy caused a meningitis outbreak, leading to 64 deaths and over 700 infections. The memories of those events still linger.
Health Secretary Robert F. Kennedy, who oversees the FDA, has shown support for easing restrictions on peptides, which just adds another layer of complexity to this situation.
